Fludara

(Fludarabine)

ApprovedSmall molecule

Fludarabine is used to treat certain types of blood cancers, particularly chronic lymphocytic leukemia (CLL) and some lymphomas. It works by damaging the DNA of cancer cells, causing them to die.[2] Fludara is currently approved and in use across 154 indications[4].[1]

Fludara is one of 2052 small molecule programs targeting Glioma. It is currently in Approved.

154

Indications

1,038

Total Trials

Active Trials

2,051

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

GliomaActive, not recruiting

Chronic Inflammatory Demyelinating PolyneuropathyRecruiting

Childhood Acute Lymphoblastic LeukemiaApproved

Systemic Lupus ErythematosusActive, not recruiting

Non-Hodgkins LymphomaApproved

MacroglobulinemiaActive, not recruiting

Nasopharyngeal CarcinomaActive, not recruiting

Aplastic AnemiaActive, not recruiting

T-Cell Acute Lymphoblastic LeukemiaActive, not recruiting

Lymphoblastic LymphomaApproved

GliomaPhase 1

Active, not recruiting

Chronic Inflammatory Demyelinating PolyneuropathyPhase 1

Recruiting

Childhood Acute Lymphoblastic LeukemiaApproved

Approved

Systemic Lupus ErythematosusPhase 1

Active, not recruiting

Non-Hodgkins LymphomaApproved

Approved

MacroglobulinemiaPhase 3

Active, not recruiting

Nasopharyngeal CarcinomaPhase 1

Active, not recruiting

Aplastic AnemiaPhase 2

Active, not recruiting

T-Cell Acute Lymphoblastic LeukemiaPhase 1

Active, not recruiting

Lymphoblastic LymphomaApproved

Approved

Showing 10 of 154 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Fludara

Sanofi

Approved

10 2

Trodelvy

Gilead

Preclinical

37 3

Adriamycin

GGynecologic Oncology Group

Preclinical

87 4

Gemzar

GGynecologic Oncology Group

Preclinical

22 5

Recentin

NNational Cancer Institute (NCI)

Preclinical

2 6

Avastin

Roche

Preclinical

4 7

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 8

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 9

Zoladex

Luye Pharma Group Ltd.

Preclinical

8 10

Naltrexone/bupropion

Novo Nordisk

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Active, not recruiting

Intraperitoneal

NCT02498912

Phase 1Active, not recruiting

Metastatic

NCT06236425

Phase 1/2Active, not recruiting

Decitabine-Primed Tandem CD19/CD20 CAR T Cells

NCT04697940

Phase 2Recruiting

Richter's Transformation

NCT05672173

Q4 2026

Phase 1Recruiting

Advanced Solid Tumors

NCT05881525

Phase 1/2Recruiting

Breast Cancer

NCT06532812

Clinical

Trials by Indication[1]

Lymphoma18 trials

Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma

Unknown status·—·Phase 1/2·NCT05776407·12 enrolled

T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT03049449·26 enrolled

Treatment of Relapsed or Refractory Epstein-Barr Virus Positive T-cell Lymphoma With hNeo-T

Recruiting·BBGI, China·Phase 1·NCT06224049·6 enrolled

Show 15 more trials

Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma

Completed· Gilead logo

Gilead·Phase 2·NCT05459571·35 enrolled

Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma

Completed· Gilead logo

Gilead·Phase 2·NCT04002401·27 enrolled

AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma

Active, not recruiting·BBenjamin Tomlinson·Phase 1·NCT03434769·31 enrolled

Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)

Terminated· Pfizer logo

Pfizer·Phase 3·NCT00562965·29 enrolled

Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

Completed· Gilead logo

Gilead·Phase 3·NCT03391466·359 enrolled

Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma

Completed· Gilead logo

Gilead·Phase 1/2·NCT02348216·307 enrolled

The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL)

Unknown status·HHenan Cancer Hospital·N/A·NCT06160362·20 enrolled

Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL

Recruiting·UUniversity Health Network, Toronto·Phase 1·NCT05963217·19 enrolled

Autologous and Allogeneic Transplant for Relapsed Lymphoma

Completed·—·Phase 1/2·NCT00802113·30 enrolled

FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)

Completed·FFate Therapeutics·Phase 1·NCT05950334·20 enrolled

Reduced Intensity Conditioning Before Partially Matched Donor Stem Cell Transplant in Treating Patients With Advanced Cutaneous T Cell Lymphoma

Withdrawn·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 1·NCT02548468

Zevalin With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Non Hodgkin Lymphoma

Unknown status·MMaisonneuve-Rosemont Hospital·Phase 1/2·NCT00807196·20 enrolled

Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma

Completed·—·Phase 2·NCT00117156·26 enrolled

A Study of WZTL-002 CAR T-cells for Adults With Relapsed Large B-cell Lymphoma

Recruiting·MMalaghan Institute of Medical Research·Phase 2·NCT06486051·60 enrolled

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

Recruiting·MMarcela V. Maus, M.D.,Ph.D.·Phase 1·NCT06026319·24 enrolled

Multiple Myeloma10 trials

CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

Unknown status·HHebei Senlang Biotechnology Inc., Ltd.·Phase 1·NCT04626752·50 enrolled

Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma

Completed·MMedical College of Wisconsin·Phase 2·NCT05032820·40 enrolled

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT06045806·79 enrolled

Show 7 more trials

Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

Terminated·AAllogene Therapeutics·Phase 1/2·NCT05000450·6 enrolled

T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT03602612·35 enrolled

MINIALO-VELCADE2005: A Study of Bortezomib (Velcade) Treated Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Progenitor Cell Transplant With no Myeloablative Conditioning

Completed·PPETHEMA Foundation·Phase 2·NCT00564200·30 enrolled

Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Recruiting·MMayo Clinic·Phase 2·NCT06940297·44 enrolled

A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT04196491·13 enrolled

Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma

Terminated·SSrinivas Devarakonda·Phase 2·NCT04205240·1 enrolled

Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma

Terminated· Gilead logo

Gilead·Phase 1·NCT03318861·17 enrolled

Leukemia8 trials

Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma

Unknown status·TThe Second Affiliated Hospital of Henan University of Traditional Chinese Medicine·Phase 1/2·NCT02685670·20 enrolled

Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma

Withdrawn·MM.D. Anderson Cancer Center·Phase 1/2·NCT04029038

CD34+ Transplants for Leukemia and Lymphoma

Not yet recruiting·GGuenther Koehne·Phase 2·NCT05565105·100 enrolled

Show 5 more trials

Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00472849·92 enrolled

Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT03856216·15 enrolled

Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT02280525·8 enrolled

Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00924170·18 enrolled

Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia

Recruiting·SSt. Jude Children's Research Hospital·Phase 1·NCT04881240·60 enrolled

Acute Lymphoblastic Leukemia8 trials

CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia

Unknown status·HHebei Senlang Biotechnology Inc., Ltd.·Phase 1·NCT04626765·50 enrolled

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

Recruiting·—·Phase 1·NCT06287944·15 enrolled

International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia

Completed·UUniversity Hospital Schleswig-Holstein·Phase 3·NCT01117441·6,136 enrolled

Show 5 more trials

A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)

Completed· Gilead logo

Gilead·Phase 1/2·NCT02614066·125 enrolled

Ma-Spore ALL 2020 Study

Recruiting·NNational University Hospital, Singapore·Phase 2·NCT06336395·500 enrolled

CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia

Recruiting·SSt. Jude Children's Research Hospital·Phase 1·NCT06777979·30 enrolled

Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia

Recruiting·TThe First Affiliated Hospital of Soochow University·Phase 1·NCT06696833·18 enrolled

Efficacy, Safety, and Pharmacokinetics of ThisCART19A Combined With Olverembatinib in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.

Active, not recruiting·TThe First Affiliated Hospital of Soochow University·Phase 1·NCT07074496·20 enrolled

Acute Myeloid Leukemia8 trials

Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia

Withdrawn·EEmory University·Phase 1·NCT02680951

A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First Treatment

Unknown status·PPETHEMA Foundation·Phase 1/2·NCT04112589·63 enrolled

A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation

Active, not recruiting· Astellas logo

Astellas·Phase 3·NCT03182244·276 enrolled

Show 5 more trials

Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia

Withdrawn·GGuenther Koehne·Phase 1/2·NCT04982354

Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Not yet recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT06954987·244 enrolled

Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia

Terminated· Gilead logo

Gilead·Phase 1·NCT04789408·15 enrolled

A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia

Terminated· Sanofi logo

Sanofi·Phase 1·NCT05712278·7 enrolled

Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia

Terminated·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1·NCT05601466·3 enrolled

105 more indications

Advanced Solid Tumors7 trials

HER2 Targeted HypoSti.CAR-T Cells in HER2 Positive Advanced Solid Tumors

Recruiting·—·Phase 1/2·NCT05681650·30 enrolled

NeoTIL in Advanced Solid Tumors

Active, not recruiting·—·Phase 1·NCT04643574·42 enrolled

ALPP CAR-T Cells for ALPP-Positive Advanced Solid Tumors

Completed·XXinqiao Hospital of Chongqing·Phase 1/2·NCT06556108·5 enrolled

Show 4 more trials

Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors

Terminated·AAdaptimmune·Phase 1·NCT04526509·12 enrolled

Allogeneic B7H3 CAR-γδT Cell Therapy for Advanced Solid Tumors

Not yet recruiting·PPeking University·Phase 1·NCT06825455·18 enrolled

NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors

Recruiting·TTCRCure Biopharma Ltd.·Phase 1·NCT05881525·18 enrolled

FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Terminated·FFate Therapeutics·Phase 1·NCT04551885·12 enrolled

Chronic Lymphocytic Leukemia7 trials

Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)

Active, not recruiting·AAllogene Therapeutics·Phase 1/2·NCT04416984·160 enrolled

CD19-specific T-cell for Chronic Lymphocytic Leukemia (CLL)

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT01653717·30 enrolled

Fludarabine and Alemtuzumab or Cyclophosphamide Followed by Peripheral Blood Stem Cell Transplant or Alemtuzumab in Treating Patients With Advanced or Progressive Chronic Lymphocytic Leukemia

Completed·GGruppo Italiano Malattie EMatologiche dell'Adulto·Phase 2·NCT00462332·86 enrolled

Show 4 more trials

Fludarabine With or Without Cyclophosphamide in Treating Patients With Advanced Chronic Lymphocytic Leukemia

Completed·GGerman CLL Study Group·Phase 3·NCT00276848·375 enrolled

Bendamustine Versus Fludarabine in Chronic Lymphocytic Leukemia (CLL)

Completed·WWiSP Wissenschaftlicher Service Pharma GmbH·Phase 2/3·NCT01423032·96 enrolled

A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies

Withdrawn·JJuno Therapeutics, Inc., a Bristol-Myers Squibb Company·Phase 3·NCT06205290

Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia

Completed·GGerman CLL Study Group·Phase 3·NCT00275054·825 enrolled

Myelodysplastic Syndrome5 trials

Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00475020·63 enrolled

CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome

Suspended·GGuenther Koehne·Phase 2·NCT05617625·50 enrolled

Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Completed·MM.D. Anderson Cancer Center·Phase 3·NCT01471444·256 enrolled

Show 2 more trials

Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT05146739·8 enrolled

Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00402558·15 enrolled

Metastatic Cancer5 trials

MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT01273181·9 enrolled

CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT01583686·15 enrolled

CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT01218867·24 enrolled

Show 2 more trials

Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT01457131·2 enrolled

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated or Viral Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab

Withdrawn·NNational Cancer Institute (NCI)·Phase 2·NCT04536922

Melanoma3 trials

Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma

Withdrawn·JJames Isaacs, MD·Phase 1·NCT06190249

Vemurafenib and White Blood Cell Therapy for Advanced Melanoma

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT01585415·12 enrolled

Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma

Completed·UUniversity Health Network, Toronto·Phase 2·NCT01883323·12 enrolled

Metastatic Melanoma3 trials

TIL-ACT After NMA Chemo with IL-2 and Nivo Rescue in Metastatic Melanoma (mMEL)

Completed·—·Phase 1·NCT03475134·18 enrolled

Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT02111863·6 enrolled

Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00509288·24 enrolled

Transplantation3 trials

Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation

Recruiting·NNantes University Hospital·Phase 2·NCT06252870·82 enrolled

Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01010217·176 enrolled

Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00038831·47 enrolled

Lymphoid Malignancies3 trials

Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT03056339·49 enrolled

Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00048737·70 enrolled

Clinical Trial Using CAR- T Cells for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies

Recruiting·NNelson Hamerschlak·Phase 1·NCT05705570·30 enrolled

B-cell Malignancies2 trials

CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies

Active, not recruiting·SStanford University·Phase 1·NCT04088864·10 enrolled

FT819 in Subjects With B-cell Malignancies

Active, not recruiting·FFate Therapeutics·Phase 1·NCT04629729·54 enrolled

Fanconi Anemia2 trials

HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

Recruiting·—·Phase 2·NCT02143830·70 enrolled

TBI Dose De-escalation for Fanconi Anemia

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2/3·NCT00352976·83 enrolled

Stem Cell Transplant2 trials

Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR

Completed·WWeill Medical College of Cornell University·Phase 2·NCT02497404·40 enrolled

Clofarabine Pre-conditioning Followed by Stem Cell Transplant for Non-remission AML

Terminated·MMilton S. Hershey Medical Center·Phase 2·NCT04002115·2 enrolled

Hematologic Malignancies2 trials

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Recruiting·TTherapeutic Advances in Childhood Leukemia Consortium·Phase 1·NCT05476770·54 enrolled

CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies

Withdrawn·BBaptist Health South Florida·Phase 2·NCT04282174

Colorectal Cancer2 trials

Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial")

Not yet recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT07411599·28 enrolled

STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma

Withdrawn·—·Phase 1·NCT06626256

Non-Small Cell Lung Cancer2 trials

T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT02133196·85 enrolled

Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors

Active, not recruiting·UUniversity of California, Irvine·Phase 1·NCT05334329·6 enrolled

Relapsed/Refractory2 trials

Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas

Recruiting·SSt. Jude Children's Research Hospital·Phase 1·NCT07222735·42 enrolled

CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies

Recruiting·MMayo Clinic·Phase 1·NCT04892277·25 enrolled

Breast Cancer2 trials

Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer

Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 1·NCT06121557·24 enrolled

TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer

Recruiting·EEssen Biotech·Phase 1/2·NCT06532812·85 enrolled

Systemic Sclerosis2 trials

A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacaptagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis

Not yet recruiting·JJuno Therapeutics, Inc., a Bristol-Myers Squibb Company·Phase 3·NCT07335562·92 enrolled

Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial

Terminated·NNorthwestern University·Phase 3·NCT01445821·44 enrolled

Stem Cell Transplantation2 trials

Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors

Terminated·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03615105·9 enrolled

Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies

Terminated·MM.D. Anderson Cancer Center·Phase 1·NCT00473551·4 enrolled

Prostate Cancer2 trials

A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer

Terminated·TTceleron Therapeutics, Inc.·Phase 1·NCT04227275·16 enrolled

PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer

Active, not recruiting·—·Phase 1·NCT03873805·14 enrolled

Safety and Efficacy2 trials

The Safety and Efficacy of the Regimen of Thiotepa + Fludarabine +Granulocyte Colony-Stimulating Factor+ Cytarabine + Busulfan in Single Unrelated Umbilical Cord Blood Transplantation

Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT07441967·44 enrolled

Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.

Terminated·MMustang Bio·Phase 1/2·NCT04109482·3 enrolled

Anemia2 trials

Stem Cell Transplantation for Sickle Cell Anemia

Completed·HHackensack Meridian Health·Phase 3·NCT01877837·30 enrolled

Treatment of Sickle Cell Anemia With Stem Cell Transplant

Terminated·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·N/A·NCT01350232·2 enrolled

Bone Marrow Transplantation2 trials

Bone Marrow Transplantation in Treating Children With Sickle Cell Disease

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00004485·50 enrolled

Reduced Intensity Conditioning (RIC) Regimen and Post-transplant Cyclophosphamide in Haploidentical Bone Marrow Transplantation in in Patients With Poor Prognosis Lymphomas

Unknown status·IIstituto Clinico Humanitas·Phase 2·NCT02049580·47 enrolled

Autoimmune Disease2 trials

A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases

Recruiting·JJuno Therapeutics, Inc., a Bristol-Myers Squibb Company·Phase 1·NCT07115745·125 enrolled

UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases

Active, not recruiting·TThe Affiliated Hospital of Xuzhou Medical University·N/A·NCT07155369·18 enrolled

Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma1 trial

Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Recruiting·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT04223765·20 enrolled

Systemic Lupus Erythematosus1 trial

Reduced Intensity Transplant in Medically Refractory Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis (SSc)

Terminated·NNew York Medical College·Phase 1·NCT00684255·1 enrolled

Hematopoietic Cell Transplantation1 trial

Cloretazine (VNP40101M) With Hematopoietic Cell Transplantation for Hematologic Malignancies

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00521859·5 enrolled

Allogeneic Hematopoietic Stem Cell Transplantation1 trial

Conditioning Regimen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00429026·40 enrolled

Glioblastoma Multiforme1 trial

Pilot Study of Autologous Anti-EGFRvIII CAR T Cells in Recurrent Glioblastoma Multiforme

Unknown status·—·Phase 1·NCT02844062·20 enrolled

PrEP1 trial

Intensified Rituimab Prephase Before FCR in Untreated B-CLL

Completed·FFrench Innovative Leukemia Organisation·Phase 2·NCT01370772·140 enrolled

Decitabine-primed Tandem CD19/CD20 CAR T Cells1 trial

Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL

Active, not recruiting·HHan weidong·Phase 1/2·NCT04697940·33 enrolled

Richter's Transformation1 trial

Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation

Recruiting·—·Phase 2·NCT05672173·20 enrolled

Relapsed or Refractory B-cell Hematologic Malignancies1 trial

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

Recruiting·MMayo Clinic·Phase 1·NCT06191887·27 enrolled

Thalassemia1 trial

Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major: A Multicenter, Prospective Clinical Study

Completed·FFirst Affiliated Hospital of Guangxi Medical University·Phase 4·NCT04009525·823 enrolled

Pancreatic Cancer1 trial

A Phase I Clinical Study of IX001 TCR-T Injection in the Treatment of Advanced Pancreatic Cancer Patients With KRAS G12V Mutation

Recruiting·SSun Yat-sen University·Phase 1·NCT06898385·9 enrolled

G-CSF1 trial

Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00822770·47 enrolled

AIN1 trial

Autologous Transplant Targeted Against Crohn's

Withdrawn·NNorthwestern University·Phase 2·NCT04154735

Infusion1 trial

Compassionate Use Re-Infusion of ATLCAR.CD30

No longer available·UUNC Lineberger Comprehensive Cancer Center··NCT03914885

Clinical Trial1 trial

Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201

Withdrawn·GGC Cell Corporation·Phase 1·NCT06341647

Sickle Cell Disease1 trial

Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease

Completed·MMonica Bhatia·Phase 1·NCT02867800·24 enrolled

Hematologic Disorder1 trial

Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders

Completed·—·Phase 2·NCT00636909·25 enrolled

Refractory Hematologic Malignancy1 trial

A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy

Recruiting·—·Phase 1·NCT06756321·9 enrolled

Dyskeratosis Congenita1 trial

Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2/3·NCT00455312·36 enrolled

Ovarian Cancer1 trial

OVSTAR TIL Trial (OVarian Cancer Co-STimulatory Antigen Receptor TIL Trial)

Withdrawn·IImmetacyte Ltd·Phase 1/2·NCT04389229

Diffuse Large B-Cell Lymphoma1 trial

Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma

Not yet recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT07164469·100 enrolled

Intraperitoneal1 trial

Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT02498912·18 enrolled

Gene Therapy1 trial

Non-Viral TCR Gene Therapy

Withdrawn·NNational Cancer Institute (NCI)·Phase 2·NCT04102436

Relapsed or Refractory1 trial

Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR

Recruiting·UUniversity Hospital Heidelberg·Phase 1/2·NCT03676504·68 enrolled

Kidney Transplant1 trial

Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor

Recruiting·AAlice Bertaina·Phase 1/2·NCT05508009·12 enrolled

Hematopoietic Stem Cell Transplantation1 trial

Pharmacokinetic Study of Fludarabine in Pediatric Hematopoietic Stem Cell Transplantation

Unknown status·SSeoul National University Hospital·Phase 2·NCT01472055·46 enrolled

Induction Chemotherapy1 trial

Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL

Unknown status·EEuropean Mantle Cell Lymphoma Network·Phase 3·NCT00209209·570 enrolled

Renal Cell Carcinoma1 trial

TIL Therapy for Metastatic Renal Cell Carcinoma

Completed·IInge Marie Svane·Phase 1·NCT02926053·5 enrolled

Solid Tumor Malignancies1 trial

GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT05003895·38 enrolled

Intestinal Cancer1 trial

A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering

Completed·IIntima Bioscience, Inc.·Phase 1/2·NCT04426669·23 enrolled

Hematopoietic Stem Cell Transplant1 trial

A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Patients

Terminated· Pfizer logo

Pfizer·Phase 1/2·NCT02614560·14 enrolled

Aplastic Anemia1 trial

Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia

Recruiting·FFred Hutchinson Cancer Center·Phase 2·NCT06752694·20 enrolled

Hematological Malignancies1 trial

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Recruiting·FFred Hutchinson Cancer Center·Phase 2·NCT04195633·60 enrolled

Hematologic Cancer1 trial

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Recruiting·IIndapta Therapeutics, INC.·Phase 1/2·NCT06119685·128 enrolled

Advanced Refractory Solid Tumors1 trial

Exploratory Study of Novel MSLN CAR-T Cell Therapy in Patients With MSLN-positive Advanced Refractory Solid Tumors

Withdrawn·SShanghai Pudong Hospital·Phase 1·NCT05531708

Treatment1 trial

A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT

Unknown status·UUniversity of Birmingham·Phase 2/3·NCT04217278·333 enrolled

Central Nervous System Lymphoma1 trial

Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/Mem T-lymphocytes) for the Treatment of Central Nervous System Lymphoma

Recruiting·—·Phase 1·NCT05625594·20 enrolled

Adult AML1 trial

CART-38 in Adult AML and MM Patients

Terminated·UUniversity of Pennsylvania·Phase 1·NCT05442580·11 enrolled

CAR T Cell Therapy1 trial

TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL

Recruiting·—·Phase 1/2·NCT06481735·30 enrolled

Neuroblastoma1 trial

Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma

Recruiting·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT03721068·18 enrolled

Gastrointestinal1 trial

A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies

Withdrawn·NNational Cancer Institute (NCI)·Phase 2·NCT06690281

Graft-versus-host-disease (GVHD)1 trial

Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation

Completed·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 1/2·NCT00429416·14 enrolled

Toxicity1 trial

Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma

Completed·UUniversity of Louisville·Phase 1·NCT02472392·10 enrolled

Memory1 trial

TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies

Recruiting·SSt. Jude Children's Research Hospital·Phase 1·NCT07052370·30 enrolled

Myeloproliferative Neoplasms1 trial

Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN)

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT02410551·4 enrolled

Acute Lymphoblastic Leukaemia1 trial

CD19 Targeted CAR T Cell Therapy in Patients With Relapsed/ Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

Unknown status·SSabz Biomedicals·Phase 1·NCT04653493·22 enrolled

Severe Aplastic Anemia1 trial

Haploidentical Stem Cell Transplantation for Children With Acquired Severe Aplastic Anemia

Unknown status·—·Phase 2·NCT01759732·10 enrolled

TED1 trial

Drosophila-generated CTL

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT01271907·3 enrolled

Relapsed/Refractory B-cell Malignancies1 trial

Study of Brexucabtagene Autoleucel (KTE-X19) for the Treatment of Individuals With Relapsed/Refractory B-Cell Malignancies

Approved for marketing· Gilead logo

Gilead··NCT04162756

Malignancies1 trial

Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT02556931·117 enrolled

Bone Marrow Transplant1 trial

Bone Marrow Transplant From Donor Using Less Toxic Conditioning for Patient With High Risk Hemoglobinopathies

Terminated·—·Phase 2·NCT00040417·15 enrolled

Myeloid Malignancies1 trial

A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies

Recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT06930651·42 enrolled

Cutaneous T-cell lymphoma1 trial

Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00506129·33 enrolled

Mesenchymal Stem Cells1 trial

Cord Blood Expansion on Mesenchymal Stem Cells

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00498316·98 enrolled

T-cell Malignancies1 trial

Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies

Recruiting·GGC Cell Corporation·Phase 1·NCT06699771·48 enrolled

Phase II1 trial

Phase II Trial GA101 Inbrutinib B CLL

Completed·FFrench Innovative Leukemia Organisation·Phase 2·NCT02666898·135 enrolled

Allogeneic Stem Cell Transplantation1 trial

Romidepsin Maintenance After Allogeneic Stem Cell Transplantation

Completed·OOhio State University Comprehensive Cancer Center·Phase 1·NCT02512497·23 enrolled

Myelodysplastic Syndromes1 trial

Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT00480987·27 enrolled

Efficacy1 trial

Efficacy of G-CSF-Priming in Elderly AML Patients

Unknown status·JJohann Wolfgang Goethe University Hospital·Phase 4·NCT00199147·250 enrolled

Imetelstat1 trial

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

Recruiting·CChildren's Oncology Group·Phase 1·NCT06247787·36 enrolled

R/R AML1 trial

Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS

Recruiting·AARCE Therapeutics, Inc.·Phase 1/2·NCT06680752·49 enrolled

Vasculitis1 trial

Hematopoietic Stem Cell Support in Vasculitis

Terminated·NNorthwestern University·Phase 1·NCT00278512·7 enrolled

Myelofibrosis1 trial

Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis

Recruiting·FFred Hutchinson Cancer Center·Phase 2·NCT04370301·20 enrolled

Liver Cancer1 trial

Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer

Recruiting·TThe Affiliated Hospital of Xuzhou Medical University·Phase 1/2·NCT05323201·15 enrolled

Graft Versus Host Disease1 trial

Post Transplant Cyclophosphamide (PTCY) as Sole Graft Versus Host Disease (GVHD) Prophylaxis for Matched Allotransplant: CYRIC

Terminated·NNantes University Hospital·Phase 2·NCT03263767·47 enrolled

aGVHD Prophylaxis1 trial

ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis

Recruiting·LLeland Metheny·Phase 2·NCT06680661·20 enrolled

Advanced NSCLC1 trial

HS-IT101 Injection for Advanced NSCLC

Not yet recruiting·QQingdao Sino-Cell Biomedicine Co., Ltd.·Phase 1·NCT07105176·12 enrolled

Metastatic1 trial

TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC

Active, not recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT06236425·7 enrolled

Immunotherapy1 trial

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01967823·11 enrolled

AML1 trial

Bisantrene Combination for Resistant AML

Unknown status·SSheba Medical Center·Phase 2·NCT04989335·29 enrolled

Immunochemotherapy1 trial

A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.

Recruiting· Ascentage Pharma Group Inc. logo

Ascentage Pharma Group Inc.·Phase 3·NCT06319456·344 enrolled

GvHD1 trial

In-Vivo Activated T-Cell Depletion to Prevent GVHD

Terminated·IIndiana University·N/A·NCT00594308·10 enrolled

Phase 11 trial

Investigator Initiated Phase 1 Study of TBI-1301

Unknown status·MMie University·Phase 1·NCT02366546·9 enrolled

Cell Therapy1 trial

CAR T-cell Therapy in Patients With Renal Dysfunction

Recruiting·NNorthside Hospital, Inc.·Phase 2·NCT05909059·20 enrolled

Donor1 trial

URMC Related Haplo-identical Donor BMT

Completed·UUniversity of Rochester·Phase 1·NCT02660281·74 enrolled

T Cells1 trial

Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL

Active, not recruiting·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT03602157·43 enrolled

Multiple Sclerosis1 trial

IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis

Suspended·IIndapta Therapeutics, INC.·Phase 1·NCT06677710·34 enrolled

Malignant Glioma1 trial

CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT01454596·18 enrolled

Carcinoma1 trial

Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma

Not yet recruiting·SSCG Cell Therapy Pte. Ltd.·Phase 1/2·NCT06505551·66 enrolled

CLL1 trial

Fludarabine, Cyclophosphamide, and Rituximab or Alemtuzumab in Treating CLL2007 CLL 2007 FMP

Completed·FFrench Innovative Leukemia Organisation·Phase 3·NCT00564512·178 enrolled

Cancers1 trial

Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers

Recruiting·NNational Cancer Institute (NCI)·Phase 1/2·NCT02830724·124 enrolled

Unspecified1 trial

Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00800839·56 enrolled

Regulatory

FDA Approval Timeline[5]

Apr 18, 1991

FLUDARA

NDA NDA020038

Sep 21, 2007

FLUDARABINE PHOSPHATE

NDA NDA022137

Dec 18, 2008

OFORTA

NDA NDA022273

Sources

References

[1]
ClinicalTrials.gov — 1038 trial records for Fludarabine. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Fludara drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Fludarabine compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Fludarabine. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA022273). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Sanofi